Before joining Rutgers Cancer Institute I completed a Clinical Fellowship in Stereotactic Radiosurgery and
Brachytherapy at the Stanford Cancer Institute in Palo Alto, California.
Not exact matches
«Contrary to expectations, the more aggressive, combined treatment did not result in superior cancer control rates
at five years follow - up, indicating that men can achieve a similar survival benefit with fewer late side effects through
brachytherapy alone.»
At two years after treatment, more than 57 percent of men who had normal sexual function prior to treatment reported poor sexual function after surgery, compared with 27 percent who reported poor sexual function after external beam radiation, 34 percent after
brachytherapy, and 25 percent after active surveillance.
NRG Oncology / RTOG 0232 is a phase III, multi-institutional trial conducted
at 68 cancer centers throughout the U.S. and Canada from 2003 to 2012 to assess whether adding EBT to transperineal interstitial permanent
brachytherapy conveyed an additional benefit in progression free survival (PFS), or control of the cancer growth,
at five years following treatment.
At five years following RT, survival rates for men who received
brachytherapy alone were comparable to those who underwent more aggressive radiation treatment.
Presenting these results
at the 3rd ESTRO Forum in Barcelona, Spain, today (Monday) Professor James Morris, from the Department of Radiation Oncology, Vancouver Cancer Centre, British Columbia Cancer Agency (BCCA), Vancouver, Canada, will say that the ASCENDE - RT1 trial is the first and only existing trial comparing low - dose - rate prostate
brachytherapy (LDR - PB) for the curative treatment of prostate cancer with any other method of radiation therapy delivery.
OC - 0485: «LDR
Brachytherapy is Superior to 78 Gy of EBRT for Unfavourable Risk Prostate Cancer: The Results of a Randomized Trial,» Highest scoring 3rd ESTRO Forum abstracts session
at 11.50 hrs (CEST) on Monday, 27 April, Main Auditorium.
«As the technology and use of HDR
brachytherapy advances, it is imperative that clinical, physics and quality assurance guidance be reviewed and updated, as necessary, to ensure quality and patient safety in the treatment delivery,» said Bruce R. Thomadsen, PhD, a professor in the Department of Medical Physics
at the University of Wisconsin School of Medicine and Public Health.
A study by researchers
at Brigham and Women's Hospital (BWH) found that
brachytherapy treatment was associated with better cause - specific survival and overall survival in women with cervical cancer.
«
At UVA, we are particularly proud of our
brachytherapy program and delivering quality
brachytherapy is a top priority for us,» he said.
«Studies have time and time again shown that
brachytherapy is the most important part of cervical cancer treatment, because it is essential to eradicating the tumor,» said Timothy Showalter, MD, a radiation oncologist
at UVA Cancer Center.
He noted that healthcare providers face a cold, hard truth when deciding whether to offer
brachytherapy, or any other treatment: «If practices don't run
at least a profit greater than zero,» he said, «then they fold.»
The white paper recommends that practitioners follow relevant guidance documents and that deviation from consensus recommendations should be supported by clinical studies or pursued in the setting of a clinical trial approved by an institutional review board; that practitioners receive training in a new procedure before beginning its practice, that the training should include a practical, «hands - on» component and that all team members directly involved with the radiation therapy decisions should participate in
at least five proctored cases before performing similar procedures independently; and that professional societies should accelerate the generation of new or updated guidance documents for the following disease sites and techniques: skin, central nervous system, gastrointestinal, lung or endobronchial and esophagus, and, while outside the charge of this panel, assess the need for updated guidance documents for accelerated partial breast irradiation using electronic
brachytherapy.
I initiated the Stereotactic Radiosurgery and
brachytherapy programs
at RWJ Somerset.
Posted in heart attack, Independent agent, insurance, life insurance, prostate cancer, PSA Tagged believe life insurance agents are honest, believe life insurance agents are knowledgeable,
brachytherapy, cancer, errors and omissions insurance, Gleason grade 6, independent life insurance agent, insurable
at standard plus rates, insurance, isn't a level playing field, life insurance, life insurance customers, lifeinsurance agent, need not apply for 5 years, prostate cancer, PSA, radioactive see implant, shop the case every year, Stage 1 cancer, sue the agent, underwriting changes, willing to send clients to competition
We thank the staff
at the Departments of Radiation Oncology and Urology
at the University of Utah Health Sciences Center, GammaWest
Brachytherapy, and the Huntsman Cancer Institute for their help in identifying and recruiting participants.